Klinikum Hochsauerland GmbH
- Address
- Schederweg 12, 59870 Meschede, Germany
Klinikum Hochsauerland GmbH - Hematologic Malignancies Research
Klinikum Hochsauerland GmbH is actively engaged in advancing treatment options for patients with hematologic malignancies, with particular emphasis on molecularly targeted therapies for acute leukemias. The center participates in multi-center clinical trials investigating innovative therapeutic approaches that combine precision medicine with conventional chemotherapy regimens.
- Acute Myeloid Leukemia (AML) with FLT3 mutations
- Targeted therapy combinations with tyrosine kinase inhibitors
- Myelodysplastic syndrome treatment strategies
The research center demonstrates expertise in FLT3-mutated AML, conducting comparative studies of gilteritinib and midostaurin in combination with intensive chemotherapy protocols. Their work focuses on evaluating novel treatment combinations including induction therapy, consolidation therapy, and maintenance strategies, contributing to the development of personalized treatment approaches for patients with specific genetic mutations in acute leukemia.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 of 4 therapeutic areas and 15 of 23 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 5 by active trials.
lock +4 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Klinikum Hochsauerland GmbH
lock Showing 1 of 8 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy of Luspatercept in Erythropoiesis-Stimulating Agent-Naive Lower-Risk Myelodysplastic Syndromes with Anemia and Transfusion Independence | Universitaet Leipzig | Phase II | Not Recruiting | Sep 2022 | — |
IMP list
lock Showing 1 of 23 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Isatuximab | 2 | Unknown | 2023-03-07 | 2024-04-03 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.